Publication date: Jan 15, 2025
In clinical practice, thymopentin (TP-5) is a commonly utilized immunomodulatory peptide drug. The relatively short half-life of TP-5, however, significantly limits its applicability in immunotherapy. Inspired by the structure of the TLR2 ligand lipopeptide Pam3CSK4, fatty acid-modified TP-5 peptides were designed and synthesized in this study. Utilizing its amphiphilicity, they were sonicated to assemble into nanoparticles with the diameters of approximately 100 nm. Compared with TP-5, TP-5 monopalmitate-modified nanoparticle has immune-activating properties both in vivo and in vitro. It markedly increased TNF-α secretion from RAW264. 7 cells and aided in the maturation of DCs. The immunogenicity of OVA model antigen was increased in vivo when capsulated by TP-5 lipopeptide nanoparticle, which considerably slowed the growth of B16-OVA melanoma. This fatty acid-modified TP-5 assembled nanoparticle offers a straightforward and useful delivery system for the design of innovative nanovaccine for cancer immunotherapy.
Concepts | Keywords |
---|---|
Immunotherapy | Cancer immunotherapy |
Lipopeptide | Cancer vaccine |
Nanoparticle | peptide assembly |
Pam3csk4 | thymopentin (TP-5) |
Vivo |
Semantics
Type | Source | Name |
---|---|---|
drug | DRUGBANK | Palmitic Acid |
drug | DRUGBANK | Thymopentin |
disease | MESH | cancer |
drug | DRUGBANK | Cycloserine |
disease | MESH | melanoma |
pathway | KEGG | Melanoma |